Relapse frequency and numbers of relapse-free patients
| Betaferon | Avonex | |||||
|---|---|---|---|---|---|---|
| Time | No of patients | RF mean reduction (%) | Relapse-free patients (%) | No of patients | RF mean reduction (%) | Relapse-free patients (%) |
| *Relapse frequency reduction was significantly greater in the Betaferon than in the Avonex group at six months (p<0.001), 12 and 18 months (p = 0.01), and 24 months (p = 0.02). The reduction was calculated on the actual basal relapse frequency in the patient subgroups at each time interval. | ||||||
| No significant difference was found between Betaferon and Avonex groups in the proportion of relapse-free patients. | ||||||
| RF, relapse frequency. | ||||||
| 0 to 6 months | 834 | −1.11* (68) | 76.01 | 647 | −0.80 (55) | 71.4 |
| 0 to 12 months | 709 | −0.97* (60.4) | 58.2 | 470 | −0.80 (55) | 55.3 |
| 0 to 18 months | 612 | −1* (63.7) | 47.9 | 322 | −0.84 (57.1) | 44.7 |
| 0 to 24 months | 503 | −1.02* (64) | 42.5 | 148 | −0.83 (56) | 39.2 |
| 0 to 30 months | 378 | −1.09 (69.7) | 40.2 | 11 | −0.69(47.6) | 27.3 |
| 0 to 36 months | 238 | −1.10 (69.6) | 36.9 | 4 | −1.33 (50) | 0 |